⚕ GalenOps CRO console
← SITE015 (POL)

SITE015-0079

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE015 (POL) (Dr. Ito) · consented 2022-05-27
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-09 (study day 97); relationship: Y

severe serious assessed 2026-08-18

Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-26 (study day 114); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 192); relationship: Y

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-05 (study day 215); relationship: Y

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-14 (study day 255); relationship: N

severe assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 321); relationship: Y

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-08-01 (study day 423); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 445); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-27 (study day 541); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.